Press release
2019-02-21
Xbrane Biopharma AB (publ) ("Xbrane") has today been informed by the Nomination Committee that Alessandro Sidoli and Saeid Esmaeilzadeh have declined re-election at the Annual General Meeting (AGM) 2019. The Nomination Committee is working to find replacements for the board members and information about any new board members will be published in connection with the notice to the AGM.
Saeid Esmaeilzadeh, co-founder and resigning board member of Xbrane comments: "As co-founder, major shareholder and board member since 2008, I have been given the privilege of seeing Xbrane growing from a small promising research project to become a leading biosimilar developer that will initiate its first clinical phase III trial during the first quarter this year. It has been a fantastic journey that has now entered into a more mature phase and I therefore feel that it is time for me to hand over and to continue to follow the Company as the main shareholder."
Alessandro Sidoli, resigning board member of Xbrane commented: "It has been very rewarding to participate in the board work in Xbrane since 2016, but for private reasons I have decided not to be available for re-election."
Anders Tullgren, Xbrane's Chairman of the Board, comments: "I would like to take this opportunity to thank Saeid and Alessandro for their exceptional efforts in building Xbrane to the company it is today. Their involvement and expertise within entrepreneurship, research and pharmaceutical development have contributed greatly to where the Company is standing today."
About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser (corp@avanza.se, +46 (0)8 409 421 20 ). For more information see www.xbrane.com.
For further information, please contact:
Martin Åmark, CEO/IR
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com
Anders Tullgren, Chairman of the Board and member of the Nomination Committee
E: valberedning@xbrane.com
This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation no. 596/2014. The information was submitted for publication, through the agency of the contact person set out above, February 21, 2019, time as mentioned above.
